Quarterly report pursuant to Section 13 or 15(d)

Significant Strategic Collaborations (Details Narrative)

v3.24.3
Significant Strategic Collaborations (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Royalty payments $ 614,243 $ 611,174 $ 1,851,464 $ 1,868,023  
Research and development expenses 367,985 1,020,618 2,246,077 2,519,137  
Prepaid expenses and other current assets 188,088   188,088   $ 603,828
Revenues 614,243 611,174 1,851,464 1,868,023  
Collaborative Agreements [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenues 0 0 0 0  
Catalent Pharma Solutions [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development expenses     2,500,000    
Prepaid expenses and other current assets 28,000   28,000   100,000
Accrued expenses and other current liabilities 100,000   100,000   0
Other assets 300,000   300,000   300,000
Scripps Research [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development expenses     900,000    
Prepaid expenses and other current assets 20,000   20,000   400,000
University Of Virginia [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development expenses     200,000   $ 0
Takeda [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Royalty payments $ 600,000 $ 1,900,000 $ 600,000 $ 1,900,000